CZ20023913A3 - Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy - Google Patents

Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy Download PDF

Info

Publication number
CZ20023913A3
CZ20023913A3 CZ20023913A CZ20023913A CZ20023913A3 CZ 20023913 A3 CZ20023913 A3 CZ 20023913A3 CZ 20023913 A CZ20023913 A CZ 20023913A CZ 20023913 A CZ20023913 A CZ 20023913A CZ 20023913 A3 CZ20023913 A3 CZ 20023913A3
Authority
CZ
Czechia
Prior art keywords
směs
zeta potential
cationic
composition
imaging
Prior art date
Application number
CZ20023913A
Other languages
Czech (cs)
English (en)
Inventor
Brita Schulze
Birgitta Sauer
Marc Dellian
Uwe Michaelis
Michael Teifel
Kurt W. Naujoks
Claudia Biro
Original Assignee
Munich Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munich Biotech Ag filed Critical Munich Biotech Ag
Publication of CZ20023913A3 publication Critical patent/CZ20023913A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CZ20023913A 2000-05-03 2001-05-03 Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy CZ20023913A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20167300P 2000-05-03 2000-05-03

Publications (1)

Publication Number Publication Date
CZ20023913A3 true CZ20023913A3 (cs) 2003-09-17

Family

ID=22746804

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20023913A CZ20023913A3 (cs) 2000-05-03 2001-05-03 Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy

Country Status (10)

Country Link
US (1) US20020034537A1 (cg-RX-API-DMAC7.html)
EP (1) EP1278512A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004511426A (cg-RX-API-DMAC7.html)
AU (2) AU2001266272B2 (cg-RX-API-DMAC7.html)
CA (1) CA2406650C (cg-RX-API-DMAC7.html)
CZ (1) CZ20023913A3 (cg-RX-API-DMAC7.html)
HU (1) HUP0301835A2 (cg-RX-API-DMAC7.html)
MX (1) MXPA02010801A (cg-RX-API-DMAC7.html)
PL (1) PL366025A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001082899A2 (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
AU2001253041A1 (en) * 2000-03-31 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Dendrimer composition for magnetic resonance analysis
US6551344B2 (en) * 2000-04-26 2003-04-22 Ev3 Inc. Septal defect occluder
SI2108362T1 (sl) * 2002-06-26 2013-08-30 Medigene Ag Kationski nosilni sistem, ki vsebuje taksan
ES2331791T5 (es) 2002-06-26 2016-01-21 Medigene Ag Método de producción de una preparación catiónica de liposomas que comprende un compuesto lipófilo
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
JP2005534718A (ja) * 2002-06-26 2005-11-17 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法
US20040024317A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for assessing capillary permeability
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
WO2004068405A2 (en) * 2003-01-25 2004-08-12 Oraevsky Alexander A High contrast optoacoustical imaging using nanoparticles
FR2855315B1 (fr) * 2003-05-23 2005-08-19 Centre Nat Rech Scient Ferrofluides stables en milieu neutre et ferrofluides modifies obtenus par modification de la surface des particules de ces ferrofluides
US9044381B2 (en) 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
RU2006144851A (ru) 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
WO2006028129A1 (ja) * 2004-09-10 2006-03-16 Toray Industries, Inc. 医薬品製剤
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
CA2638899C (en) * 2005-10-20 2016-01-05 Georgetown University Tumor-targeted nanodelivery systems to improve early mri detection of cancer
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP2009536215A (ja) * 2006-05-02 2009-10-08 ユニバーシティ オブ マイアミ 局所コエンザイムｑ１０製剤、及び疼痛、疲労、並びに創傷の治療
US20070281034A1 (en) * 2006-05-15 2007-12-06 Kirpotin Dmitri B Magnetic microparticles comprising organic substances
EP2040674B1 (en) * 2006-05-18 2010-07-07 MediGene AG Cationic liposomal preparations for the treatment of rheumatoid arthritis
WO2008045976A2 (en) * 2006-10-10 2008-04-17 Squicor Compositions and methods for treating and diagnosing cancers
US20110002851A1 (en) * 2006-11-03 2011-01-06 Medigene Ag Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US8329161B2 (en) * 2008-05-01 2012-12-11 National Health Research Institutes Red blood cell-derived vesicles as a nanoparticle drug delivery system
US8690762B2 (en) * 2008-06-18 2014-04-08 Raytheon Company Transparent endoscope head defining a focal length
WO2010014792A2 (en) 2008-07-30 2010-02-04 Sterling Lc Method and device for incremental wavelength variation to analyze tissue
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010053916A2 (en) 2008-11-04 2010-05-14 Sterling Lc Method and device for wavelength shifted imaging
US20100135912A1 (en) * 2008-12-02 2010-06-03 Gambhir Sanjiv S Magnetotactic bacteria mri positive contrast enhancement agent and methods of use
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US8717428B2 (en) * 2009-10-01 2014-05-06 Raytheon Company Light diffusion apparatus
WO2011041720A2 (en) 2009-10-01 2011-04-07 Jacobsen Stephen C Method and apparatus for manipulating movement of a micro-catheter
US8828028B2 (en) 2009-11-03 2014-09-09 Raytheon Company Suture device and method for closing a planar opening
US10238886B2 (en) * 2009-11-18 2019-03-26 Nanobacterie Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
US10029115B2 (en) * 2011-04-08 2018-07-24 Sanovas Intellectual Property, Llc Photodynamic therapy for tumors with localized delivery
CN102419370B (zh) * 2011-08-04 2014-08-27 武汉理工大学 用于检测小鼠组织内Bt杀虫蛋白的免疫磁小体及其制备方法
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
EP4006550B1 (en) * 2012-08-29 2026-06-17 Inguran, LLC Composition for magnetic removal or identification of damaged or compromised cells or cellular structures
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US10143762B2 (en) 2013-12-13 2018-12-04 Mercury Assel Management Co., Ltd. Articular cartilage imaging composition
EP3116392A4 (en) 2014-03-14 2018-02-14 Rhode Island Hospital Nanocarriers and their processing for diagnostics and therapeutics
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
CA3063916A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
CN108751397A (zh) * 2018-05-31 2018-11-06 北京北华中清环境工程技术有限公司 添加功能化磁性微球利用mbr进行煤制气废水处理的方法
WO2021221167A1 (ja) * 2020-04-30 2021-11-04 国立大学法人 長崎大学 ガン治療薬及びガン治療方法
CN112754996B (zh) * 2021-03-16 2023-03-31 江西省科学院生物资源研究所 一种鱼精蛋白短肽修饰的紫杉醇脂质体及其制备方法
WO2023064316A1 (en) * 2021-10-11 2023-04-20 Arizona Board Of Regents On Behalf Of Arizona State University Composite ink formulations for endoscopic imaging

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635180A (en) * 1988-02-17 1997-06-03 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5230883A (en) * 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
EP0783325B2 (en) * 1994-09-27 2004-03-31 Amersham Health AS Contrast agent
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
DE19912502A1 (de) * 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
PL203128B1 (pl) * 1999-09-09 2009-08-31 Univ California Liposom zawierający taksan i zastosowanie liposomu kationowego

Also Published As

Publication number Publication date
WO2001082899A3 (en) 2002-06-13
AU2001266272B2 (en) 2005-09-15
AU6627201A (en) 2001-11-12
WO2001082899A2 (en) 2001-11-08
JP2004511426A (ja) 2004-04-15
WO2001082899A9 (en) 2003-05-08
CA2406650A1 (en) 2001-11-08
MXPA02010801A (es) 2004-09-06
PL366025A1 (pl) 2005-01-24
CA2406650C (en) 2009-07-21
EP1278512A2 (en) 2003-01-29
HUP0301835A2 (hu) 2003-09-29
US20020034537A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001266272B2 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
Lakkadwala et al. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma
AU2001266272A1 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20240042063A1 (en) LINKED AND OTHER pH-TRIGGERED COMPOUNDS
Abdellatif et al. Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Wang et al. In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma
Wu et al. An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques
Wang et al. Bovine serum albumin as a versatile platform for cancer imaging and therapy
Wen et al. Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer
Guo et al. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy
JP4813712B2 (ja) 薬物−担体複合体およびその使用方法
Wang et al. MMP-2-controlled transforming micelles for heterogeneic targeting and programmable cancer therapy
JP2004511426A5 (cg-RX-API-DMAC7.html)
Huang et al. Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma
JP7772847B2 (ja) 抗がん剤の送達のためのステレオコンプレックス
US20190192686A1 (en) Targeted nanodroplet emulsions for treating cancer
Wu et al. Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach
CN103446588B (zh) 靶向型诊疗联用药物及其制备方法和应用
Shimizu et al. Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors
Zhao et al. Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features
Hunt Precision targeting of intraperitoneal tumors with peptideguided nanocarriers
Meng et al. A Hypoxia-Sensitive Drug Delivery System Constructed by Nitroimidazole and its Application in the Treatment of Hepatocellular Carcinoma: A Hypoxia-Sensitive Drug Delivery System in the Treatment of Hepatocellular Carcinoma
US11160881B2 (en) Dendrimer compositions for use in angiography
JP2022514463A5 (cg-RX-API-DMAC7.html)
CN109589413B (zh) 靶向胎盘样硫酸软骨素a的多肽、靶向纳米颗粒及其制备方法和应用